Newsroom

Ivy Center Postdoctoral Fellow Costanza Lo Cascio, PhD, was featured in the latest issue of Oncology Fellows. The article highlights the importance of a pharmacokinetic and pharmacodynamic-guided approach in neuro-oncology preclinical trials to fast-track development of the most promising brain-penetrant drugs for glioblastoma treatment.

The Ivy Brain Tumor Center's Pharmacodynamics Core Leader An-Chi Tien has been awarded a one-year, $50,000 grant for work in genetic analysis of meningioma tumors by the American Brain Tumor Association. 

Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Center, is the recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care. 

The Ivy Center was featured on Health Tomorrow on PBS’ Arizona Horizon to discuss the challenges facing brain tumor patients and the efforts by the Ivy Center to overcome those obstacles. More brain tumor patients are treated at the Ivy Center and Barrow Neurological Institute than in any other facility in the U.S., explained Dr. Nader Sanai, director of the Ivy Center and director of Neurosurgical Oncology at Barrow Neurological Institute.

Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly pediatric brain cancer with a 2% five-year survival rate. To provide therapeutic options for patients and families, SonALAsense is partnering with clinicians at the Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix Children's Hospital, and other sites to conduct a phase 1/2 clinical trial for sonodynamic therapy (SDT). This is the first SDT trial for children.

Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.

The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment. 

In this Neurosurgery Blog Tumor Series, Dr. Nader Sanai, director of the Ivy Brain Tumor Center, discusses the unique challenges for brain tumor drug development and how the Ivy Center's Phase 0 clinical trials are creating a new paradigm.

Dr. Nader Sanai spoke with local news station, ABC15 about new developments in brain cancer research and treatment on the fourth anniversary of Senator John McCain's death.

Dr. Kelly Braun from the Ivy Brain Tumor Center at Barrow Neurological Institute spoke with Good Morning Arizona reporter Tess Rafols, about new developments and treatments for brain cancer.